GlycoErase™ GALNT13 Knockout Human Prostate Cancer Cell 22RV1 (CAT#: GLJF-0525-JF287)

Description	The GALNT13 knockout 22RV1 cell line, lacking polypeptide N-acetylgalactosaminyltransferase 13 initiating O-linked glycosylation, allows for the study of O-linked glycosylation disruption in prostate cancer; the absence of GALNT13 may affect cell surface glycosylation patterns and O-glycosylation dependent functions relevant to prostate tumor cells.
Product Type	KO Cell Lines
Species	Human
Cell Morphology	Epitheloid cells, adherent
Passage Ratio	1:3~1:10
Cell Line	22RV1
Primary Disease	Prostate Adenocarcinoma
Lineage	Prostate

Cell Viability	>90%
Sterility Test	The sterility test indicated an absence of microbial growth.
Identity Test	STR identification
Mycoplasma Test	Negative
Virus Test	Negative for HIV, HBV and HCV.
Genetic Stability Testing	We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation	PCR, Sanger Sequencing
Culture Medium	DMEM & FBS & RPMI
Application	Functional assay
Size	1 M cells/vial*2
Product Format	Frozen
Shipping	Dry ice
Availability Status	Made to order
Handling Notes	Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer	This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.

Target	GALNT13
Full Name	Polypeptide N-acetylgalactosaminyltransferase 13
Alternative Name	KIAA1918, GalNAc-T13
Location	2q23.3
Gene ID	114805
Summary	Initiates O-linked glycosylation of mucins by transferring GalNAc to serine or threonine residues.